437 related articles for article (PubMed ID: 21645262)
1. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
Dolly JO; Wang J; Zurawski TH; Meng J
FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
[TBL] [Abstract][Full Text] [Related]
2. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain.
Dolly JO; O'Connell MA
Curr Opin Pharmacol; 2012 Feb; 12(1):100-8. PubMed ID: 22188874
[TBL] [Abstract][Full Text] [Related]
3. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.
Wang J; Zurawski TH; Meng J; Lawrence G; Olango WM; Finn DP; Wheeler L; Dolly JO
J Biol Chem; 2011 Feb; 286(8):6375-85. PubMed ID: 21138836
[TBL] [Abstract][Full Text] [Related]
4. Importance of two adjacent C-terminal sequences of SNAP-25 in exocytosis from intact and permeabilized chromaffin cells revealed by inhibition with botulinum neurotoxins A and E.
Lawrence GW; Foran P; Mohammed N; DasGupta BR; Dolly JO
Biochemistry; 1997 Mar; 36(11):3061-7. PubMed ID: 9115981
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
Edupuganti OP; Ovsepian SV; Wang J; Zurawski TH; Schmidt JJ; Smith L; Lawrence GW; Dolly JO
FEBS J; 2012 Jul; 279(14):2555-67. PubMed ID: 22607388
[TBL] [Abstract][Full Text] [Related]
6. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Wang J; Zurawski TH; Meng J; Lawrence GW; Aoki KR; Wheeler L; Dolly JO
FASEB J; 2012 Dec; 26(12):5035-48. PubMed ID: 22942075
[TBL] [Abstract][Full Text] [Related]
7. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
8. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.
Meng J; Wang J; Lawrence G; Dolly JO
J Cell Sci; 2007 Aug; 120(Pt 16):2864-74. PubMed ID: 17666428
[TBL] [Abstract][Full Text] [Related]
9. A closer look to botulinum neurotoxin type A-induced analgesia.
Guo BL; Zheng CX; Sui BD; Li YQ; Wang YY; Yang YL
Toxicon; 2013 Sep; 71():134-9. PubMed ID: 23747735
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxins: mechanisms of action, antinociception and clinical applications.
Wheeler A; Smith HS
Toxicology; 2013 Apr; 306():124-46. PubMed ID: 23435179
[TBL] [Abstract][Full Text] [Related]
11. On the action of botulinum neurotoxins A and E at cholinergic terminals.
Washbourne P; Pellizzari R; Rossetto O; Bortoletto N; Tugnoli V; De Grandis D; Eleopra R; Montecucco C
J Physiol Paris; 1998 Apr; 92(2):135-9. PubMed ID: 9782457
[TBL] [Abstract][Full Text] [Related]
12. A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFα-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons.
Nugent M; Yusef YR; Meng J; Wang J; Dolly JO
Neuropharmacology; 2018 Aug; 138():257-266. PubMed ID: 29906413
[TBL] [Abstract][Full Text] [Related]
13. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.
Marinelli S; Vacca V; Ricordy R; Uggenti C; Tata AM; Luvisetto S; Pavone F
PLoS One; 2012; 7(10):e47977. PubMed ID: 23110146
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of action of botulinum toxins and neurotoxins].
Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
[TBL] [Abstract][Full Text] [Related]
15. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis.
Washbourne P; Pellizzari R; Baldini G; Wilson MC; Montecucco C
FEBS Lett; 1997 Nov; 418(1-2):1-5. PubMed ID: 9414082
[TBL] [Abstract][Full Text] [Related]
16. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release.
Foran P; Lawrence GW; Shone CC; Foster KA; Dolly JO
Biochemistry; 1996 Feb; 35(8):2630-6. PubMed ID: 8611567
[TBL] [Abstract][Full Text] [Related]
17. Uptake of botulinum neurotoxin into cultured neurons.
Keller JE; Cai F; Neale EA
Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain.
Wang J; Casals-Diaz L; Zurawski T; Meng J; Moriarty O; Nealon J; Edupuganti OP; Dolly O
Neuropharmacology; 2017 May; 118():223-232. PubMed ID: 28347837
[TBL] [Abstract][Full Text] [Related]
19. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
20. Is the light chain subcellular localization an important factor in botulinum toxin duration of action?
Fernández-Salas E; Ho H; Garay P; Steward LE; Aoki KR
Mov Disord; 2004 Mar; 19 Suppl 8():S23-34. PubMed ID: 15027051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
